Skip to main content
Aker BioMarine logo

Aker BioMarine — Investor Relations & Filings

Ticker · AKBM ISIN · NO0010886625 LEI · 549300V34T6VWDSYWE64 OL Agriculture, forestry and fishing
Open in API
Filings indexed 508 across all filing types
Latest filing 2024-07-12 Interim / Quarterly Rep…
Country NO Norway
Listing OL AKBM

About Aker BioMarine

https://www.akerbiomarine.com/

Aker BioMarine is a biotechnology innovator that sustainably harvests Antarctic krill to develop and supply krill-derived ingredients. The company's core business focuses on producing ingredients for the human health and nutrition markets, including nutraceuticals and dietary supplements. It also serves the aquaculture and animal feed sectors with specialized products. Aker BioMarine leverages its vertically integrated supply chain and scientific research to create a portfolio of products that extends to agricultural biostimulants and pharmaceutical applications. The company is committed to sustainable operations and the scientific validation of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Second quarter 2024 results for Aker BioMarine
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Second Quarter Report 2024' and contains comprehensive financial statements, segment reviews, and operational highlights for the period. It provides detailed financial data (Net sales, EBITDA, etc.) for the quarter and year-to-date, which fits the definition of an Interim/Quarterly Report (IR). It is not merely an announcement or a summary, but the full report itself. Q2 2024
2024-07-12 English
Second quarter 2024 results for Aker BioMarine
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly report for Aker BioMarine ASA for Q2 2024. It contains detailed financial statements (P&L, Balance Sheet), segment-level performance analysis, operational highlights, and management commentary on business units. It is not a mere announcement or certification, as it provides substantive financial data and analysis for the specified period. Therefore, it is classified as an Interim/Quarterly Report. Q2 2024
2024-07-12 English
Second quarter 2024 results for Aker BioMarine
Earnings Release Classification · 100% confidence The document explicitly states it contains the "Second quarter 2024 results for Aker BioMarine" and provides key financial highlights (Revenues, Adjusted EBITDA) for the period, along with management commentary. This structure is characteristic of an Earnings Release (ER). Although it mentions a webcast presentation will follow, the document itself is the initial announcement of the period's financial performance, not the presentation or the transcript. It is too detailed for just an RPA, and it is not the comprehensive annual report (10-K) or a full interim report (IR), but rather the initial summary release. Q2 2024
2024-07-12 English
Aker BioMarine ASA – Invitation to presentation of the second quarter 2024 results
Report Publication Announcement Classification · 98% confidence The document is an invitation announcing the release date (Friday 12 July 2024) and time (07:00 CET) for the second quarter 2024 results, followed by a webcast presentation and Q&A session at 09:00 CET. This is a classic announcement about the upcoming release of financial results and the associated investor event. Since the document itself is short and primarily serves to announce *when* the results will be available and *how* to attend the presentation, it fits the definition of a Report Publication Announcement (RPA) better than the actual Earnings Release (ER) or Call Transcript (CT). It is announcing the publication of the results and the presentation.
2024-07-10 English
Aker BioMarine ASA – Agreement to sell its ownership position in Feed Ingredients
M&A Activity Classification · 99% confidence The document announces a definitive agreement for the sale of a business unit (Feed Ingredients) for a specific enterprise valuation (USD 590 million). It details the transaction structure, expected shareholder value distribution (extraordinary dividend), and the resulting focused business structure. This type of announcement, detailing a major corporate transaction like a divestiture, falls under the category of M&A Activity (TAR). Although it is a significant corporate event, it is not a standard regulatory filing like a 10-K, an earnings release (ER), or a capital raise (CAP). It is a specific announcement about a transaction, fitting the definition of M&A Activity (TAR). The document length is moderate (5064 chars), suggesting it is the primary announcement, not just a brief notice of publication (RPA/RNS).
2024-07-03 English
Aker BioMarine ASA – Registration of share capital increase
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the 'Registration of share capital increase' related to an Employee Share Purchase Program. It details the new registered share capital and the number of shares, which directly relates to a change in the company's capital structure. This aligns perfectly with the definition for 'Share Issue/Capital Change' (SHA). Although it is a short announcement, the content is the primary event (registration/change) rather than an announcement of a separate report, making SHA a better fit than RPA or RNS.
2024-06-12 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.